SEATTLE, Dec. 3, 2013 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.
(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)
Immunosequencing is an emerging field where NGS technology is specifically tailored to sequence T and B cell receptors, enabling an in-depth characterization of the adaptive immune response.
clonoSEQTM, is a CLIA-certified immunosequencing diagnostic used to monitor Minimal Residual Disease (MRD), the cancerous cells remaining after treatment, in patients with T and B cell malignancies. The technology tracks a single clone that acts as a genetic “tag” of a leukemia or lymphoma. Flow cytometry is the current standard for tracking MRD, but the technique can be inaccurate and difficult to standardize.
At ASH, data will be presented that establishes a correlation between greater sensitivity of detection of rare clones using clonoSEQ and survival in patients with blood cancers. “clonoSEQ is the first sequencing-based diagnostic to demonstrate a significant improvement compared to flow cytometry. These data show we can better predict relapse and make informed clinical decisions to improve patient care,” says Dr. Harlan Robins, Scientific Founder of Adaptive Biotechnologies.
immunoSEQTM, Adaptive’s research-based immunosequencing assay, is being used extensively to monitor the immune repertoire over time after transplantation. At ASH, Adaptive and its collaborators will present data demonstrating a survival benefit due to a decreased risk of infection from the reconstitution of a diverse immune repertoire post-transplant, as measured by immunoSEQTM.
Adaptive, having recently received a broad allowance on the use of multiplex Polymerase Chain Reaction (PCR) to sequence T and B cell receptors, is also the only immunosequencing provider with a proven ability to control for bias caused by PCR amplification. “Adaptive pioneered the field of immunosequencing and then enhanced it by developing a Synthetic Immune System to ensure the quantitative accuracy that is essential for clinical decision-making,” said Chad Robins, co-founder and CEO of Adaptive. “Without this level of rigor, validated survival benefits for patients will be difficult to achieve.”
Oral presentations highlighting the utility of clonoSEQ for monitoring MRD in B-ALL:
Abstract #163: Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19
Presenter:Michael Kalos, MD (University of Pennsylvania)
Session: 801. Gene Therapy and Transfer: Progress in vector development and gene therapy of acquired diseases
Presentation Time:Sunday, December 8, 2013: 5:00 PM-6:30 PM
Location: Riverside Rooms - R02-R03 (Ernest N. Morial Convention Center)
Abstract #69: Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy
Presenter:Marco Davila, MD, PhD
Program: Oral Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Novel Immune-Based Therapies and Novel Targets
Time:Sunday, December 8, 2013: 5:00 PM-6:30 PM
Location: La Nouvelle Ballroom C (Ernest N. Morial Convention Center)
Abstract #919: Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study
Presenter:Michael Pulsipher, MD
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation
Time:Tuesday, December 10, 2013: 7:30 AM-9:00 AM
Location: 208-210 (Ernest N. Morial Convention Center)
Poster presentations further validating clonoSEQ:
Abstract #1341: On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing
Presenter:David Wu, MD, PhD
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Time:Saturday, December 7, 2013: 5:30 PM-7:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #2550: Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH
Presenter:David Wu, MD, PhD
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II
Time:Sunday, December 8, 2013: 6:30 PM-8:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #2614: Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm
Presenter:Anna Sherwood, PhD
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II
Time:Sunday, December 8, 2013: 6:30 PM-8:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #4141: Analysis Of T Cell Receptor Repertoire Reveals Evidence For Antigen-Specific Response In CLL Lymph Nodes
Presenter: Marta Pasikowska, MD
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
Time:Monday, December 9, 2013: 6:00 PM-8:00 PM
Location: Hall E (Ernest N. Morial Convention Center)
Oral presentations highlighting the importance of immunocompetency post-transplant:
Session #731: Clinical Allogeneic and Autologous Transplantation - Results: Haploidentical and Umbilical Cord Blood Transplantation
Session Chair:Colleen Delaney, MD
Time:Sunday, December 8, 2013: 5:00 PM-6:30 PM
Location: 208-210 (Ernest N. Morial Convention Center)
Poster presentations highlighting the importance of immunocompetency post-transplant:
Abstract #3302: Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire
Presenter: Ioannis Politikos, MD
Session: 722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster II
Time:Sunday, December 8, 2013: 6:30 PM-8:30 PM
Location: Hall G (Ernest N. Morial Convention Center)
Abstract #4483: Evaluation Of Immunocompentence In Tolerant Chimeric Recipients Of Hematopoietic Stem Cell/Renal Transplants
Presenter:Suzanne Ildstad, MD
Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III
Time:Monday, December 9, 2013: 6:00 PM-8:00 PM
Location: Hall G (Ernest N. Morial Convention Center)
Abstract #4618: Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period
Presenter:Ute Burkhardt, PhD
Session: 722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune
Reconstitution: Poster III
Time:Monday, December 9, 2013: 6:00 PM-8:00 PM
Location: Hall G (Ernest N. Morial Convention Center)
Presentations showcasing the continual validation of Adaptive’s immunosequencing assays:
Abstract #1376: All Clones Are Not Equal: Somatic Hypermutation Significantly Enhances The Utility Of Tumor Tagging Rearrangements At IG Light Chain Loci In B Cell Malignancy
Presenter:Christopher Carlson, PhD
Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Time:Saturday, December 7, 2013: 5:30 PM-7:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #1045: Assessing B Lymphocyte Clonal Diversity, Expansion, and Convergent Evolution By High-Throughput Sequencing Of Rearranged IGH Segments From Naïve and Memory Repertoires
Presenter:William DeWitt
Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster I
Time:Saturday, December 7, 2013: 5:30 PM-7:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #2292: On The Organization Of Human T Cell Receptor Loci
Presenter:Amir Toor, MD
Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster II
Time: Sunday, December 8, 2013: 6:30 PM-8:30 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #3486: Frequency Of Gene Usage and Copy Number Variation Within The Rearranged Immunoglobin Heavy-Chain Variable Locus Based On Immune Repertoire Sequencing
Presenter:Mark Rieder, PhD
Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster III
Time:Monday, December 9, 2013: 6:00 PM-8:00 PM
Location: Hall E (Ernest N. Morial Convention Center)
Abstract #3480: Annotation Of Pseudogenous Gene Segments By Massively Parallel Sequencing Of Rearranged Lymphocyte Receptor Loci
Presenter:Ryan Emerson, PhD
Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster III
Time:Monday, December 9, 2013: 6:00 PM-8:00 PM
Location: Hall E (Ernest N. Morial Convention Center)
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (“Adaptive” or the “Company”) is a pioneer in immunosequencing diagnostics, with a focus in oncology. The Company leverages advances in next generation sequencing (“NGS”) to profile T-Cell and B-Cell Receptors (“TCRs” and “BCRs”). This breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company’s first clinical application, clonoSEQTM, is for monitoring Minimal Residual Disease (“MRD”) in blood-based cancers. The Company recently launched clonoSEQTM as a CLIA certified Laboratory Developed Test (“LDT”) in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care. Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes (“TIL”) and to create a reliable measure of “immunocompetency” to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQTM.
SOURCE Adaptive Biotechnologies Corporation
Help employers find you! Check out all the jobs and post your resume.
